NEW YORK (GenomeWeb News) - Agendia said today that it has signed a license agreement with the Erasmus University Medical Center in Rotterdam, the Netherlands, giving it exclusive rights to a genetic profile that predicts resistance to tamoxifen.
Agendia said it will validate the tamoxifen profile in collaboration with the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital.
Once validated, the company intends to add the profile to its MammaPrint gene expression-based breast cancer recurrence test.
In addition to the license agreement, the three organizations have entered a research collaboration focused on "next-generation hormonal therapies for breast cancer," Agendia said.
Financial terms of the agreement were not disclosed.